• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国私人保险人群中酒精性肝硬化的高负担。

The high burden of alcoholic cirrhosis in privately insured persons in the United States.

机构信息

Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.

Department of Statistics, University of Michigan, Ann Arbor, MI.

出版信息

Hepatology. 2018 Sep;68(3):872-882. doi: 10.1002/hep.29887. Epub 2018 May 20.

DOI:10.1002/hep.29887
PMID:29579356
Abstract

UNLABELLED

Alcoholic cirrhosis (AC) is a major cause of liver-related morbidity and mortality in the United States. Rising rates of alcohol use disorders in the United States will likely result in more alcoholic liver disease. Our aim was to determine the prevalence, health care use, and costs of AC among privately insured persons in the United States. We collected data from persons aged 18-64 with AC (identified by codes from the International Classification of Diseases, Ninth and Tenth Revisions) enrolled in the Truven MarketScan Commercial Claims and Encounters database (2009-2015). We determined yearly prevalence, weighted to the national employer-sponsored, privately insured population. Using competing risk analysis, we estimated event rates for portal hypertensive complications and estimated the association between AC and costs as well as admissions and readmissions. In 2015, 294,215 people had cirrhosis and 105,871 (36%) had AC. Mean age at AC diagnosis was 53.5 years, and 32% were women. Over the 7 years queried, estimated national cirrhosis prevalence rose from 0.19% to 0.27% (P < 0.001) and for AC from 0.07% to 0.10% (P < 0.001). Compared to non-AC, AC enrollees were significantly more likely to have portal hypertensive complications at diagnosis and higher yearly cirrhosis and alcohol-related admissions (25 excess cirrhosis admissions and 6.3 excess alcohol-related admissions per 100 enrollees) as well as all-cause readmissions. Per-person costs in the first year after diagnosis nearly doubled for AC versus non-AC persons (US$ 44,835 versus 23,319).

CONCLUSION

In a nationally representative cohort of privately insured persons, AC enrollees were disproportionately sicker at presentation, were admitted and readmitted more often, and incurred nearly double the per-person health care costs compared to those with non-AC. (Hepatology 2018).

摘要

目的

在美国,酒精性肝硬化(AC)是与肝脏相关的发病率和死亡率的主要原因。美国酗酒障碍发病率的上升可能会导致更多的酒精性肝病。我们的目的是确定美国私人保险人群中 AC 的患病率、医疗保健利用和费用。我们从患有 AC(通过国际疾病分类,第九和第十修订版的代码识别)的 18-64 岁人群中收集数据,这些人参加了 Truven MarketScan 商业索赔和就诊数据库(2009-2015 年)。我们确定了每年的患病率,并对全国雇主赞助的私人保险人群进行了加权。使用竞争风险分析,我们估计了门脉高压并发症的事件发生率,并估计了 AC 与费用以及入院和再入院之间的关联。2015 年,有 294215 人患有肝硬化,其中 105871 人(36%)患有 AC。AC 诊断时的平均年龄为 53.5 岁,32%为女性。在调查的 7 年中,全国肝硬化患病率从 0.19%上升到 0.27%(P < 0.001),AC 患病率从 0.07%上升到 0.10%(P < 0.001)。与非 AC 患者相比,AC 患者在诊断时更有可能患有门脉高压并发症,并且每年肝硬化和酒精相关的入院率更高(每 100 名患者中有 25 例肝硬化入院和 6.3 例酒精相关入院),以及全因再入院率。与非 AC 患者相比,AC 患者在诊断后第一年的人均医疗费用几乎翻了一番(44835 美元对 23319 美元)。

结论

在一个具有全国代表性的私人保险人群队列中,AC 患者的病情明显更严重,入院和再入院的次数更多,并且与非 AC 患者相比,人均医疗保健费用几乎增加了一倍。(Hepatology 2018)。

相似文献

1
The high burden of alcoholic cirrhosis in privately insured persons in the United States.美国私人保险人群中酒精性肝硬化的高负担。
Hepatology. 2018 Sep;68(3):872-882. doi: 10.1002/hep.29887. Epub 2018 May 20.
2
Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis.私营医疗保险患者酒精相关性肝硬化治疗中性别差异的研究。
Alcohol Clin Exp Res. 2019 Feb;43(2):334-341. doi: 10.1111/acer.13944. Epub 2019 Jan 22.
3
Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis.酒精性肝硬化的费用超过所有其他肝硬化病因的总和:一项全国和州住院患者调查分析。
Dig Dis Sci. 2019 Jun;64(6):1460-1469. doi: 10.1007/s10620-019-5471-7. Epub 2019 Jan 23.
4
Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.2001年至2005年美国雇主赞助的私人保险女性人群中滴虫病每例直接成本及总体负担的估计数。
Sex Transm Dis. 2009 Jun;36(6):395-9. doi: 10.1097/OLQ.0b013e318199d5fe.
5
Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States.美国私人保险患者慢性乙型肝炎的诊断率。
JAMA Netw Open. 2020 Apr 1;3(4):e201844. doi: 10.1001/jamanetworkopen.2020.1844.
6
Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.参保人群中多发性硬化症患者的患病率、支出、利用率及支付情况。
Neurology. 2002 Jan 8;58(1):37-43. doi: 10.1212/wnl.58.1.37.
7
Burden and Cost of Outpatient Hemorrhoids in the United States Employer-Insured Population, 2014.美国雇主参保人群中 2014 年痔病门诊患者的负担和费用。
Am J Gastroenterol. 2019 May;114(5):798-803. doi: 10.14309/ajg.0000000000000143.
8
Prevalence of High-Burden Medical Conditions Among Young and Middle-Aged Adults With Pediatric-Onset Medical Conditions: Findings From US Private and Public Administrative Claims Data.患有儿科起病的医疗状况的年轻和中年成年人中具有高负担的医疗状况的流行率:来自美国私人和公共行政索赔数据的研究结果。
Int J Health Policy Manag. 2019 Nov 1;8(11):629-635. doi: 10.15171/ijhpm.2019.62.
9
Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.对医疗保险优势计划参保者或商业保险覆盖的肺动脉高压患者的肺动脉高压相关住院费用进行特征分析:一项回顾性数据库研究。
Am J Manag Care. 2015 Jan;21(3 Suppl):s47-58.
10
Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients.糖尿病与慢性丙型肝炎患者发生失代偿期肝硬化的较高风险相关。
J Clin Gastroenterol. 2017 Jan;51(1):70-76. doi: 10.1097/MCG.0000000000000566.

引用本文的文献

1
Association between serum homocysteine levels and advanced hepatic fibrosis in alcohol-related liver disease: A cross-sectional study of NHANES.血清同型半胱氨酸水平与酒精性肝病中晚期肝纤维化的关联:一项美国国家健康与营养检查调查(NHANES)的横断面研究
Medicine (Baltimore). 2025 Jul 25;104(30):e43395. doi: 10.1097/MD.0000000000043395.
2
Blockade of the estrogen receptor alpha-pregnane X receptor axis protects ovariectomized mice against ethanol-induced hepatotoxicity.雌激素受体α-孕烷X受体轴的阻断可保护去卵巢小鼠免受乙醇诱导的肝毒性。
J Biol Chem. 2025 May 15;301(6):110238. doi: 10.1016/j.jbc.2025.110238.
3
Perfluorooctane sulfonate (PFOS) exposure and alcohol-associated liver disease severity in a mouse chronic-binge ethanol feeding model.
在小鼠慢性暴饮乙醇喂养模型中全氟辛烷磺酸(PFOS)暴露与酒精性肝病严重程度的关系
Toxicol Sci. 2025 May 10. doi: 10.1093/toxsci/kfaf066.
4
A prolonged activated partial thromboplastin time indicates poor short-term prognosis in patients with hepatic encephalopathy: insights from the MIMIC database.活化部分凝血活酶时间延长提示肝性脑病患者短期预后不良:来自MIMIC数据库的见解
Front Med (Lausanne). 2025 Feb 13;12:1514327. doi: 10.3389/fmed.2025.1514327. eCollection 2025.
5
LIVE-SMART: A sequential, multiple assignment randomized trial to reduce falls in cirrhosis.LIVE-SMART:一项旨在减少肝硬化患者跌倒的序贯、多组分配随机试验。
Hepatol Commun. 2025 Feb 19;9(3). doi: 10.1097/HC9.0000000000000626. eCollection 2025 Mar 1.
6
Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.酒精使用障碍与酒精相关肝病:新定义、筛查与治疗
Gastroenterol Hepatol (N Y). 2024 Nov;20(11):662-671.
7
Cost-effectiveness of an oral cholate challenge test for the management of patients at risk for large esophageal varices.口服胆酸挑战试验用于管理大食管静脉曲张风险患者的成本效益分析。
PLoS One. 2024 Nov 22;19(11):e0313006. doi: 10.1371/journal.pone.0313006. eCollection 2024.
8
Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States.美国2040年前胃肠道癌发病率和死亡率的差异、趋势及预测
Am J Gastroenterol. 2024 Nov 12;120(6):1367-1380. doi: 10.14309/ajg.0000000000003198.
9
Alcohol and Hepatocellular Carcinoma.酒精与肝细胞癌。
Clin Liver Dis. 2024 Nov;28(4):633-646. doi: 10.1016/j.cld.2024.06.007. Epub 2024 Jul 23.
10
Molecular targets of PXR-dependent ethanol-induced hepatotoxicity in female mice.PXR 依赖性乙醇诱导的雌性小鼠肝毒性的分子靶点。
Biochem Pharmacol. 2024 Oct;228:116416. doi: 10.1016/j.bcp.2024.116416. Epub 2024 Jul 8.